OncoMatch/Gastric / Stomach Cancer/HER2 (ERBB2)
Gastric / Stomach CancerHER2 (ERBB2) Clinical Trials
HER2 overexpression or amplification (IHC 3+ or IHC 2+/FISH+) occurs in approximately 20% of gastric and gastroesophageal junction adenocarcinomas and is the strongest predictive biomarker in this disease. Trastuzumab added to platinum/fluoropyrimidine chemotherapy is the first-line standard for HER2-positive advanced gastric cancer; trastuzumab deruxtecan (T-DXd) is approved in the second-line setting. Trials investigate T-DXd combinations, bispecific HER2 antibodies, and novel ADCs across HER2 expression levels.
Top recruiting HER2 (ERBB2) Gastric / Stomach Cancer trials
Ranked by phase and US site count. See all 45 trials matched to your profile →
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Browse other molecular targets with active Gastric / Stomach Cancer trials.